• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

Technologies.org

Technology Trends: Follow the Money

  • Technology Events 2023-2024
  • Sponsored Post
    • Make a Contribution
  • Technology Jobs
  • Technology Markets
    • Venture Capital
  • About
  • Contact

Coronavirus (COVID-19) Update: White House Press Briefing by FDA Commissioner Stephen M. Hahn, M.D

March 7, 2020 By admin Leave a Comment

Thank you for joining me today to provide updated information about the current state of diagnostic testing during this coronavirus public health emergency.

First, I want to thank the dedicated professionals of the FDA for their round the clock, multi-layered approach to the coronavirus outbreak. I’d also like to thank our partners from across the federal government, such as HHS, CDC, CMS, and BARDA. I had the opportunity to speak with my CDC colleagues, Dr. Bob Redfield and Dr. Anne Schuchat this morning to exchange the most current updates from our respective agencies. I am appreciative of the leadership of President Trump, Vice President Pence, and Secretary Azar and of the partnership and the cross-collaborative work our team performs together every day within the Department of Health and Human Services and across the entirety of the U.S. government to our public health mission.

This is a dynamic and constantly evolving situation. Not just day by day, but hour by hour. I also recognize this has led to some confusion about the quantity of diagnostic tests available and how many patients can be tested.

As the President, Vice President, and Secretary have promised, we are committed to being transparent about this situation, so today I will provide you the most comprehensive and up to date information about the status of diagnostic tests and information about who should be tested.

Before we get to the most current numbers, I’d like to provide an explanation about the role of diagnostics in emergencies, and why this particular situation has been a bit more complex than past outbreaks. I hope this will provide much needed clarity to the American public.

First, we should paint a picture of what is happening globally. The World Health Organization (or WHO) also supports the establishment of testing capability by collecting and sharing that information provided by developers, including protocols for diagnostic testing and testing assays. We’ve seen reports about the WHO distributing a diagnostic test to countries. To be clear, the WHO does not have its own test that it is distributing globally. It has only posted on its website protocols from some test developers, such as the CDC.

Also, internationally, different countries have had different levels of success with their diagnostic test development. For example, we understand from a test developer that there have been problems with the performance of several tests being used that country. Despite media reports on testing capabilities in other countries, I do not want to speculate on the policies and procedures related to the development and validation of tests in other countries.

In the U.S., we have policies in place that strike the right balance during public health emergencies of ensuring critical independent review by the scientific and public health experts and timely test availability.

As I have mentioned previously regarding the development process, in the U.S., the CDC is typically the first developer of a diagnostics for an emergency because they have access to clinical specimens and viral samples before other developers. They work to make this material available for other developers to use in validation of their tests. The CDC test can and often does become the basis for tests that other developers create. The CDC test is an incredibly important tool during a public health emergency response.

In this case, once the CDC had access to clinical specimens, and similar to past emergencies, the FDA immediately began working with our public health partners at the CDC to support the development of the CDC diagnostic test, including working with the CDC through their emergency use authorization process.

There were manufacturing problems with the CDC test. While those issues have been resolved, at the time, this created complications for expanding access for public health laboratories and other developers who might use the CDC test as the basis for development of their own test. What’s important here is that we have a test that the American people can trust.

The FDA and CDC worked together to quickly resolve the manufacturing issues and utilize a third-party manufacturer to assist with manufacturing the tests for not only the state public health labs, but also for commercial distribution to nonpublic health labs, including academic medical centers, community hospitals, and more.

That manufacturer has been quickly producing tests for distribution. It is important to note, though, that each lot of these tests must undergo quality control testing by CDC, an essential and required last step to assure that each test provides accurate results. Quality testing, distribution of tests, and verification of the tests in labs can take a few days, although FDA, CDC staff, and the laboratory community are working around the clock to speed up these processes.

Separate from the manufacturing challenges, the CDC has been quickly working to update the clinical recommendations for testing patients based on emerging information about the presentation of the disease in patients. The COVID-19 virus has a long incubation period and mild cases can go undetected because patients may have so few symptoms, thus adding to the difficulty with diagnosing the disease. The CDC test is a high quality test and it’s important to remember that false negatives or positives can be detrimental to making sure we are treating patients early, without delay, and also not quarantining healthy individuals.

With that landscape, let me provide you with a comprehensive update on numbers:

CDC has shipped tests sufficient to test about 75,000 individuals for COVID-19 to Public Health Laboratories. And all Public Health Laboratories that originally received a CDC test have received replacement tests. Laboratories in areas with the highest need for testing based on the outbreak have received additional tests, however, all state public health labs now have tests available to them.
As of today, the CDC test shipped to public health labs has been able to test more than 3,500 specimens from 1,583 patients.
Additionally, as of last night, more than 1.1 million tests have been shipped to nonpublic health labs.
The manufacturer, IDT, is distributing these tests nationwide, although the first batch of tests were shipped to the states of California and Washington based on confirmed clusters in those areas.
IDT currently has another 400,000 tests which have undergone and passed final quality control check and we expect those tests to ship to labs on Monday.
Another manufacturer’s tests will be undergoing a quality control check. That batch of 640,000 tests could ship as early as Monday.
IDT and other manufacturers believe they can scale up production so that by the end of next week tests, an additional 4 million tests could be shipped.
This does not include the ramp up expected by large commercial or academic labs.

A very important point I want to make here is about the reporting of numbers. I promised yesterday to explain a bit about the distinction between the number of tests shipped compared to the number of patients that could be tested. The actual number of tests that have shipped is larger than the number of patients that can be tested. With current estimates (and this could change), 2.1 million tests would roughly translate to 850,000 Americans being able to undergo testing.

We’ve been asked a lot of questions about capacity of the labs to run these tests. When a lab will begin offering tests, and how many tests per day a lab has the ability to conduct, will depend on each individual lab. There are additional steps each lab needs to take after receipt of tests in order to deploy those tests, including verification of the tests and training for staff if they have never run the test before. The volume for testing (or the number of tests that can be run) will also vary widely and will depend on the size of the lab.

Finally, I want to end with a quick update on ways that FDA is supporting all diagnostic developers during this time. FDA received its first request for an EUA template on January 22nd and we sent the template to them the same day. We have since received over 100 requests for the template. Of those, 36 sought our assistance with development and validation of tests they plan to bring through the Emergency Use Authorization process. We are talking to them around the clock, and our door is open for any developers who want to have a test for use in the U.S.

Additionally, we issued a policy last weekend to achieve more rapid testing in the U.S. We have provided regulatory relief and clarity to encourage the development of new diagnostic tests for Americans. Under that new policy, we have heard from 7 labs, 4 of whom already have begun patient testing.

Rest assured, we are dedicating all available resources to address this outbreak and expedite the availability of diagnostics.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

SOURCE U.S. Food and Drug Administration
http://www.fda.gov

Filed Under: Tech Tagged With: COVID-19, Coronavirus

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Market Analysis

Cloudflare is introducing the concept of the “connectivity cloud”
Robotic Revolution: Japan’s Surging Industrial Robot Market and China’s Dominance
China’s Poaching of Water Technologies from the West: A Serious Concern
Market Scenario of China Banning Exports of Rare Earth Materials and Electric Batteries
Navigating Markets through a 4-Dimensional Research Data Model
A Markov Chain-Based Approach for Forecasting Emerging Technologies: An Extended Analysis
Identifying Resilient Stocks Poised for a Strong Comeback Amidst Economic Recovery

Market Research Media

The Evolution of RSS Feeds: A Media Analyst’s Perspective
AI-Enhanced 4-Dimensional Market Dynamics Analysis: Unveiling Trends, Segmentation, Behavior, and Evolution through Markov Chain Modeling
Autotutoring Market: Personalized Learning and Technological Innovation at the Forefront
Integration of Generative AI and Large Language Models for Enterprises
The Decline of Chinese Media Under Authoritarian Rule: Economic Implications
Algorithmic Bias in Media Recommendation Systems: Unveiling Challenges and Pursuing Fairness
U.S. Federal IT Market Forecast

Secondary Sidebar

Tech Events

Smart City Expo 2023 Reshapes Urban Futures with Unprecedented Participation and Innovation Showcase
SAP SBN User Conference is taking place on October 17-18, 2023 in Oslo, Norway
2023 European Conference on Optical Communication (ECOC) in Glasgow, Scotland, October 2-4, 2023
Bloomberg Technology Summit, October 24t, 2023, London
Imagine 2023, Edge AI Conference, September 27, 2023, Computer History Museum, Mountain View, California

Venture Capital

Silverflow Secures €15 Million Investment to Revolutionize Global Payment Processing
Myrror Security, an Israeli company specializing in application security for organizations using open-source packages, has officially launched with $6 million in seed funding
Iron Nation Launches Volunteer Emergency Impact Fund to Support Israeli Start-ups Affected by Recent Conflict
UnitX, a robotics company specializing in AI vision systems, secures $5 Million
UserEvidence, a customer voice platform, secured $9 million in Series A funding

Footer

Recent Posts

  • Aalyria and Airbus Collaborate on High-Speed Aerial and Spaceborne Networks
  • Entrepreneurship Program at Argonne National Laboratory Opens Applications for Startups
  • Toyota is nearing mass production of solid-state batteries
  • Cloudflare and Meta Partner to Democratize Access to Llama 2 Open Source Large Language Model (LLM)
  • Bridging the Semiconductor Workforce Gap: Intel’s Innovative Educational Initiatives
  • German Government and Bavaria Invest €300M in ams OSRAM Semiconductor Tech
  • Innovative Ship Concept: Providing Zero-Carbon Nuclear Energy for Defense and Disaster Relief
  • Linux Foundation Launches OpenTofu: A New Open Source Alternative to Terraform
  • Introducing the NETGEAR Nighthawk Tri-Band Mesh WiFi 6E System: Exceptional Range and Performance for the Modern Home
  • Apple unveils iPhone 15 Pro and iPhone 15 Pro Max

App Coding

Creating an app that generates a description of an image using ChatGPT
A developer’s job isn't just to churn out code every day
Common Pitfalls in Agile Development and How to Avoid Them
How to Debug Your Code: Best Practices
Join Our Team as an App Coder - Build Cutting-Edge Applications

API Coding

Template API
How to connect to the DALL-E API
Mastering API Design: Principles for Creating Effective and User-Friendly Interfaces
Leveraging API and IP Intelligence for Improved Cybersecurity
How to teach yourself API coding

Blockchaining

Blockchain Technology: Ownership Through Equity Tokenization
What is a blockchain domain?
How safe are NFTs as digital assets
Building a Decentralized VPN Using Blockchain Technology
Brands to Shop: Empowering Shopping Club Membership through Blockchain

Calendarial

Smart City Expo 2023: “The New Urban Era” in a Record-Breaking Edition, November 7-9, 2023, Barcelona
Apple: “Scary Fast” virtual event, October 30, 2023
Our hearts go out to the people of Israel
The 30th annual RegTech Convention, 21-22 November 2023
Private Equity International’s Responsible Investment Forum Europe 2023 will take place on November 8-9, 2023, in London, England

Copyright © 2022 Technologies.org

Media Partners: Market Analysis & Market Research and Exclusive Domains

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT